Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
Title:
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
Author:
Dreyling, Martin Doorduijn, Jeanette Giné, Eva Jerkeman, Mats Walewski, Jan Hutchings, Martin Mey, Ulrich Riise, Jon Trneny, Marek Vergote, Vibeke Shpilberg, Ofer Gomes da Silva, Maria Leppä, Sirpa Jiang, Linmiao Stilgenbauer, Stephan Kerkhoff, Andrea Jachimowicz, Ron D Celli, Melania Hess, Georg Arcaini, Luca Visco, Carlo van Meerten, Tom Wirths, Stefan Zinzani, Pier Luigi Novak, Urban Herhaus, Peter Benedetti, Fabio Sonnevi, Kristina Hanoun, Christine Hänel, Matthias Dierlamm, Judith Pott, Christiane Klapper, Wolfram Gözel, Döndü Schmidt, Christian Unterhalt, Michael Ladetto, Marco Hoster, Eva
Appeared in:
Lancet
Paging:
Volume 403 () nr. 10441 pages 2293-2306
Year:
2024
Contents:
Publisher:
The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license